Lasting Reduction in Toxicity Seen for MRI-Guided SBRT for Prostate Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 27, 2024 -- Magnetic resonance imaging (MRI) guidance for aggressive margin reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces two-year toxic effects, according to a study published online Nov. 13 in European Urology.
Amar U. Kishan, M.D., from the University of California, Los Angeles, and colleagues conducted a secondary analysis of a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer to compare the impact of AMR with MRI guidance versus computed tomography (CT) guidance.
The researchers found that the cumulative incidence of two-year physician-scored toxicity, defined as grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxic effects, were lower with MRI guidance. The cumulative incidence rates of late grade ≥2 toxicity at two years were 27 versus 51 percent for MRI- versus CT-guided SBRT for GU toxicity and 1.4 versus 9.5 percent for GI toxicity. The odds of a clinically relevant deterioration in bowel function according to the Expanded Prostate Cancer Index Composite-26 score and in the Sexual Health Inventory in Men score were significantly lower with MRI-guided SBRT (odds ratios, 0.444 and 0.366, respectively). The odds of a deterioration for other quality-of-life metrics did not differ significantly.
"This study adds strong evidence that the enhanced precision and accuracy afforded by MRI-guided SBRT leads to significantly fewer urinary, bowel, and sexual side effects for men receiving prostate SBRT," Kishan said in a statement.
Several authors disclosed ties to the pharmaceutical and medical device industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Racial Differences Seen in Prostate Cancer Care Quality
WEDNESDAY, July 30, 2025 -- Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared with White men, according to a...
Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer
TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.